Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Taxane and platinum chemotherapy
9 evidence topics · 11 sources
Docetaxel: FDA-approved indication and TAX327 overall survival
| Outcome | Docetaxel plus prednisone every 3 weeks | Mitoxantrone plus prednisone every 3 weeks |
|---|---|---|
| Median survival, months (95% CI) | “18.9 (17.0-21.2)” | “16.5 (14.4-18.6)” |
| Hazard ratio (95% CI) | “0.761 (0.619-0.936)” | Not applicable |
Docetaxel: TAX327 publication
“As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cabazitaxel: FDA-approved indication and TROPIC overall survival
| Outcome | Cabazitaxel plus prednisone | Mitoxantrone plus prednisone |
|---|---|---|
| Median survival, months (95% CI) | “15.1 (14.1-16.3)” | “12.7 (11.6-13.7)” |
| Hazard ratio (95% CI) | “0.70 (0.59-0.83)” | Not applicable |
Cabazitaxel: TROPIC publication
“At the cutoff for the final analysis (Sept 25, 2009), median survival was 15·1 months (95% CI 14·1-16·3) in the cabazitaxel group and 12·7 months (11·6-13·7) in the mitoxantrone group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common clinically significant grade 3 or higher adverse events were neutropenia (cabazitaxel, 303 [82%] patients vs mitoxantrone, 215 [58%]) and diarrhoea (23 [6%] vs one [<1%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cabazitaxel versus a second androgen receptor pathway inhibitor after docetaxel: CARD
| Outcome | Cabazitaxel plus prednisone or prednisolone plus G-CSF | Abiraterone plus prednisone or prednisolone, or enzalutamide |
|---|---|---|
| Median rPFS, months (95% CI) | “8.0 (5.7 to 9.2)” | “3.7 (2.8 to 5.1)” |
| rPFS hazard ratio (95% CI) | “0.54 (0.40 to 0.73)” | Not applicable |
| Median OS, months (95% CI) | “13.6 [11.5; 17.5]” | “11.0 [9.2; 12.9]” |
| OS hazard ratio (95% CI) | “0.64 [0.46; 0.89]” | Not applicable |
Cabazitaxel versus a second androgen receptor pathway inhibitor: CARD publication
“Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“tumor response was noted in 36.5% and 11.5% (P = 0.004)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements on chemotherapy after androgen receptor pathway inhibitors
Platinum chemotherapy: guideline treatment-selection factors
Carboplatin added to cabazitaxel: randomized phase 2 trial
“At a median follow-up of 31·0 months (IQR 20·5–37·1), the combination improved the median progression-free survival from 4·5 months (95% CI 3·5–5·7) to 7·3 months (95% CI 5·5–8·2; hazard ratio 0·69, 95% CI 0·50–0·95, p=0·018).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 2 study, the most common grade 3–5 adverse events were fatigue (7 [9%] of 79 in the cabazitaxel group vs 16 [20%] of 81 in the combination group), anaemia (3 [4%] vs 19 [23%]), neutropenia (3 [4%] vs 13 [16%]), and thrombocytopenia (1 [1%] vs 11 [14%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote